Market research
TYME Tyme Technologies Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- 0.0%
- Beta
- 0.92
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US90238J1034
- Market cap
- 54M
- P/E ratio
- Not available
- Analyst target
- 9.5
- Dividend yield
- 0.0%
- Beta
- 0.92
About
About Tyme Technologies Inc
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TYME discussion.
5 years, 4 months ago
Tyme Technologies, Inc is currently in a long term downtrend where the price is trading 20.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Tyme Technologies, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 12.0% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 33.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Tyme Technologies, Inc gets an overall score of 2/5.